April 2009: Financing Risk

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: April 2009: Financing Risk
Released on: May 19, 2009. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Follow us:
In This Episode:
    In the current economic climate, early-stage research-focused biotech companies are suffering from a severe shortage of cash.
  • Summary
  • Transcript
  • Participants
  • Company
In the current economic climate, early-stage research-focused biotech companies are suffering from a severe shortage of cash. Large pharmaceutical companies, with access to funds, are examining their R&D costs but need to maintain product pipelines as they teeter on the edge of patent cliffs. Could these unique circumstances represent new opportunities to share the financial risks in drug development?

PharmaDeals Reference: 1100

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
One of the key issues to arise from the current economic climate is the significant drop in funding from early stage of discovery to proof of concept amongst biotech companies. Biotechnology enterprises continue to have a severe need for cash to fund the further development of their pre-proof of concept therapies. Equally, pharmaceutical companies have limited resources to take compounds through to full commercialisation and are also having to look carefully at their R&D costs, yet balance this with an imperative to maintain product pipelines as their more mature products come off patent. Currently, pharmaceutical companies are looking at short-term solutions hence the rise in recent M&A activity. All these provide relatively immediate improvements in quarterly earnings as these companies face dramatic patent cliffs. This new consolidation provides an opportunity for some assets within these companies to be spun-out. Pharmaceutical companies are getting more comfortable with this concept. However, the big issue of funding these spin-out companies still remains. The good news is that these assets, unlike biotech developed projects, have already passed the pharmaceutical test. Thus pharmaceutical companies have an opportunity to work with venture capital and private equity groups to potentially finance and merge these new entities into existing biotechnology companies and thus boost their portfolios and their cash position. Option agreements by the pharmaceutical companies provide a means to reduce the transactional costs and risks of future licensing transactions going forward. Although somewhat complex, these arrangements will ensure that product pipelines remain strong and provide a means for all parties to share and mitigate risk.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:

• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK